News

Silvergate Pharmaceuticals receives FDA approval for Qbrelis

Friday, July 29, 2016

FDA Approves Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older 
Continue Reading

New Open Access Journal Publishes its First Issue, "Nanoparticles in Medicine"

Wednesday, July 20, 2016

Bioengineering & Translational Medicine’s special issue focuses on the targeting, optimization and clinical applications of nanoparticles 

FIREFLY MEDICAL RECEIVES INVESTMENT FROM CARLTON-HARVEY GROUP TO EXPAND BUSINESS OPERATIONS

Tuesday, July 19, 2016

July 19, 2016—Fort Collins, CO—Firefly Medical Inc. (www.iveamobility.com), which produces the IVEA, a transformative patient mobility solution, announced today a strategic investment from Carlton-Harvey Group (CHG) ( www.carltonharveygroup.com), a private investment firm specializing in funding and management strategies for emerging medical device companies.

In addition to making a significant equity investment in the company, CHG will also assume management control of Firefly Medical. CHG Principal Trevor Carlton will serve as chief executive officer, and CHG Principal Stuart Harvey will serve as president. Current Firefly Medical CEO, Patrick Bols, will join the executive committee and become board chairman.

Carlton is a medical device expert who has led a multinational medical device company to consistent year-over-year double digit sales and EBITA growth and completed an M&A transaction worth $680M. Harvey has developed global sales organizations, driving millions in sales in multiple countries. He specializes in sales strategy, operations and management.

“This investment will help ensure that Firefly has the resources and expertise it needs to realize the IVEA’s full market potential,” says Bols. “We’re pleased to partner with CHG, because they have the foresight to identify the opportunity before them and the experience to pursue it effectively.”

“Almost immediately we recognized that the IVEA is a solution that could transform the industry,” says Carlton. “It’s a great story and a great product, and we look forward to working with Firefly to make the IVEA the new standard of care in hospitals around the world.”
 
Continue Reading

PierianDx and ArcherDX Announce Partnership Benefiting NGS Clinical Labs

Tuesday, July 19, 2016

ST LOUIS/BOULDER (July 12, 2016) – ArcherDX and PierianDx today announced co-marketing and licensing agreements that will provide enhanced NGS testing capabilities to clinical labs. Under the terms of the agreement, PierianDx will integrate Archer® targeted NGS testing pipelines into the PierianDx Clinical Genomicist Workspace™ (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting. 

Highly potent autophagy-inducing peptides now exclusively available from Novus Biologicals, a Bio-Techne brand

Monday, July 18, 2016

MINNEAPOLIS, Minnesota [July 18, 2016] – Bio-Techne Corporation, a global life sciences company providing innovative biotechnology research tools and instruments for the academic, biotech, pharma and diagnostic communities announced today the launch of several new products for the study of autophagy. The Tat-L11, Tat-D11, and Tat-L11S Control Peptides are available exclusively under the Novus Biologicals brand. Autophagy is a biological process that allows the orderly degradation and recycling of cellular components and is involved in numerous pathological/physiological processes, including cancer, metabolic and neurodegenerative disorders, and cardiovascular/pulmonary diseases.  

​MPLN partners with ArcherDX to offer Archer NGS assays to global biopharma customers

Monday, July 18, 2016

Boulder, COLORADO – ArcherDX, Inc., has announced that Molecular Pathology Laboratory Network, Inc. (MPLN) is now a Certified Service Provider of Archer® FusionPlex® NGS assays. MPLN will offer a custom sarcoma analysis service that includes the FusionPlex Sarcoma NGS assay as part of their services to customers in the biotechnology and pharmaceutical industries.
 

ViroCyt acquired by Sartorius

Monday, July 18, 2016

VIROCYT® ACQUIRED BY SARTORIUS  

LABS, Inc. Rebrands

Friday, July 15, 2016

CENTENNIAL, Colo.--(BUSINESS WIRE)--LABS, Inc., a laboratory services company specialized for transplantation and biomedical applications, announced today that it has adopted an updated mission statement, revealed a new tagline, and unveiled a new logo. 

Array BioPharma files NDA for advanced melanoma treatment

Tuesday, July 05, 2016

Via PharmaBiz.com (India)